Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Faus & Moliner Abogados is a Spanish law firm that has been specializing in pharma and life sciences law since 1997. Founding partner Jordi Faus explains how having a comprehensive…
Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate…
Sanofí’s general manager for Spain, Margarita Lopez Acosta, comments on the company’s “Play to Win” strategy, the presence of the French giant in Spain and the leading role of the…
The outbreak of the COVID-19 pandemic put an end to more than five years of economic growth in Spain. But the country was not alone. Due to strict containment measures,…
After decades of investment, Catalonia has secured its healthcare and life sciences hub status, accounting for more than half of Spain’s pharma exports and with more clinical trials than any…
Its unorthodox name reflecting a somewhat unconventional approach, mAbxience has achieved some significant milestones in its short history, including becoming the only privately-owned company in the world with less than…
Kyowa Kirin’s head of the South Europe cluster, Norberto Villarrasa, explains the Japanese company’s presence in Spain, its focus on rare diseases and onco-haematology, and comments on the challenges around…
UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the importance of R&D – UCB spent around 28…
João Madeira, General Manager of Viatris Spain discusses the position of the Spanish affiliate and the challenges of a generous decentralised healthcare system. He also outlines some of Viatris’ successes…
In 2021, a hospital in Barcelona managed to get approval for the first European-developed CAR-T cell therapy. Aided by a little girl and her mother, a team of doctors at…
Boston Scientific’s Spain country coordinator, Carlos Sabrido, analyses the Spanish med-tech market, comments on the transformation of Boston Scientific – going from a medical devices to a health solutions company…
Spain is playing an important role in the production of COVID-19 vaccines with four Spanish companies involved in vaccine manufacturing projects, three of them doing fill and finish and one…
See our Cookie Privacy Policy Here
